The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Shunjun Jiang
Shunjun Jiang
Hengrui Liang
Hengrui Liang
Zhichao Liu
Zhichao Liu
Shen Zhao
Shen Zhao
Yalei Zhang
Yalei Zhang
Jianxing He
Jianxing He

The oncologist, 2020.

Cited by: 0|Bibtex|Views18|Links
WOS

Abstract:

Anlotinib can benefit patients with advanced NSCLC with BM and is highly potent in the management of intracranial lesions. Its special effect on BM and cerebral tissue merits further investigation. (ClinicalTrials.gov ID: NCT02388919).

Code:

Data:

Your rating :
0

 

Tags
Comments